“…Laminin-332, a heterotrimer consisting of an α3-, β3-, and γ2-chain encoded by the genes LAMA3 , LAMB3 , and LAMC2 , respectively [1-5], is undetectable in most of these patients. More than 90% of them carry homozygous or compound-heterozygous premature termination codons (PTCs) in one of the three genes [6, 7], resulting in complete absence of functional laminin-332 and thus in a devastating clinical course with widespread erosions of the epidermis and mucous membranes, loss of protein, fluids, and iron, compromised wound healing, excessive formation of granulation tissue, respiratory complications, infections, and death within the first years of life [2, 4, 7]. Despite elaborate therapeutic approaches, including allogeneic stem cell transplantation, protein replacement therapy, and gene therapy, which has not yet been evaluated in clinical trials [7-12], severe generalized JEB cannot be cured so far.…”